Pharmafile Logo

sipuleucel-T

- PMLiVE

Pfizer keeps nose ahead of rivals with new Ibrance approval

FDA licenses new indication for the breast cancer treatment

- PMLiVE

Pfizer resurrects its OTC bid for Viagra in the UK

Confirms MHRA review of new pharmacist-supplied status has begun

National Institute for Health and Care Excellence NICE logo

NICE knocks-back Shire’s pancreatic cancer drug Onivyde

Final guidance rules it's not a cost-effective use of NHS resources

- PMLiVE

Merck, Pfizer get first OK for checkpoint inhibitor avelumab

FDA approval for rare skin cancer drug

Biogen Idec building

NICE backtracks on Biogen’s multiple sclerosis drug Zinbryta

Recommends the treatment after new cost effectiveness and a discount provided

National Institute for Health and Care Excellence NICE logo

NICE agrees £20m cost ceiling for new drugs

New budget test set to begin from April and could delay uptake of new medicines

- PMLiVE

Pfizer launches new antibiotic Zavicefta in UK and Germany

Biopharmaceutical company Pfizer releases MDR antibiotic

- PMLiVE

Servier cleared to start US trials CAR-T therapy

FDA rules studies of its Pfizer-partnered drug can be resumed

Deal Watch February 2017

Actelion, Johnson & Johnson, Sanofi, Takeda and more feature in this month's pharma deals round-up

Marketing strategy in complex environments

Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through what...

Blue Latitude Health

- PMLiVE

NICE set to back Parsabiv for kidney disease complication

Draft guidance recommends Amgen treatment for secondary hyperparathyroidism

- PMLiVE

Merck & Co and Pfizer take aim at diabetes with trio of new drugs

File ertugliflozin-based products with EU and US regulators

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links